DOP2013000041A - Quelatos de oligonucleótidos para su uso en la supresión o reducción de reacciones en el punto de inyección - Google Patents
Quelatos de oligonucleótidos para su uso en la supresión o reducción de reacciones en el punto de inyecciónInfo
- Publication number
- DOP2013000041A DOP2013000041A DO2013000041A DO2013000041A DOP2013000041A DO P2013000041 A DOP2013000041 A DO P2013000041A DO 2013000041 A DO2013000041 A DO 2013000041A DO 2013000041 A DO2013000041 A DO 2013000041A DO P2013000041 A DOP2013000041 A DO P2013000041A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- oligonucleotide
- chelates
- reactions
- suppression
- reduction
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 6
- 238000006243 chemical reaction Methods 0.000 title 1
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
- 150000001768 cations Chemical class 0.000 abstract 3
- 230000009920 chelation Effects 0.000 abstract 2
- 239000002184 metal Substances 0.000 abstract 2
- 206010022095 Injection Site reaction Diseases 0.000 abstract 1
- 230000010100 anticoagulation Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000013522 chelant Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Abstract
La presente divulgación describe la quelación ampliamente activa de diversos cationes metálicos divalentes2+ mediante cualquier oligonucleótido (ON), sin importar el tamaño o la modificación. Este efecto de quelación es específico para cationes que son divalentes (o de valencia mayor) y da como resultado la formación de quelatos de oligonucleótidos que no se comportan como sales. Se describe en la presente una composición novedosa de un quelato de ON preparado usando cualquier ON y un catión metálico divalente y métodos para suprimir la anticoagulación y/o las reacciones en el sitio de inyección subcutánea y/o tolerabilidad mejorada con oligonucleótidos mediante el uso de quelatos de ON durante la administración de oligonucleótidos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37525710P | 2010-08-20 | 2010-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2013000041A true DOP2013000041A (es) | 2017-12-15 |
Family
ID=45594559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2013000041A DOP2013000041A (es) | 2010-08-20 | 2013-02-14 | Quelatos de oligonucleótidos para su uso en la supresión o reducción de reacciones en el punto de inyección |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US8513211B2 (es) |
| EP (1) | EP2605794B1 (es) |
| JP (1) | JP5775581B2 (es) |
| KR (3) | KR101606495B1 (es) |
| CN (2) | CN103768086B (es) |
| AU (1) | AU2011291401B2 (es) |
| BR (1) | BR112013003875B1 (es) |
| CA (2) | CA2855690C (es) |
| CL (1) | CL2013000445A1 (es) |
| CO (1) | CO6670525A2 (es) |
| CR (1) | CR20130069A (es) |
| CU (1) | CU20130022A7 (es) |
| CY (1) | CY1118207T1 (es) |
| DK (1) | DK2605794T3 (es) |
| DO (1) | DOP2013000041A (es) |
| EA (1) | EA026660B1 (es) |
| EC (1) | ECSP13012449A (es) |
| ES (1) | ES2598556T3 (es) |
| GT (1) | GT201300040A (es) |
| HR (1) | HRP20161333T1 (es) |
| HU (1) | HUE029521T2 (es) |
| IL (1) | IL224237A (es) |
| LT (1) | LT2605794T (es) |
| MX (1) | MX340294B (es) |
| MY (1) | MY160961A (es) |
| NZ (1) | NZ606364A (es) |
| PH (1) | PH12013500192B1 (es) |
| PL (1) | PL2605794T3 (es) |
| PT (1) | PT2605794T (es) |
| RS (1) | RS55245B1 (es) |
| SG (1) | SG187165A1 (es) |
| SI (1) | SI2605794T1 (es) |
| SM (1) | SMT201600370B (es) |
| WO (1) | WO2012021985A1 (es) |
| ZA (1) | ZA201300497B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2049664T1 (sl) | 2006-08-11 | 2012-04-30 | Prosensa Technologies Bv | Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev |
| US7943591B2 (en) | 2007-05-11 | 2011-05-17 | Adynxx, Inc. | Gene expression and pain |
| ES2639852T3 (es) | 2007-10-26 | 2017-10-30 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarrestar los trastornos musculares |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| NZ627896A (en) | 2012-01-27 | 2016-11-25 | Biomarin Technologies B V | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| LT2841578T (lt) | 2012-04-23 | 2017-09-25 | Biomarin Technologies B.V. | Rnr moduliuojantys oligonukleotidai su pagerintomis savybėmis, skirti neuromuskulinių susirgimų gydymui |
| PT2846839T (pt) * | 2012-05-10 | 2019-05-29 | Adynxx Inc | Formulações para a administração de ingredientes ativos |
| SMT202100319T1 (it) * | 2012-05-18 | 2021-09-14 | Replicor Inc | Composizioni e metodi del complesso oligonucleotide chelato polipeptidico |
| AR091065A1 (es) * | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| EP2870246B1 (en) | 2012-07-03 | 2019-09-11 | BioMarin Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
| SG11201501255PA (en) * | 2012-08-30 | 2015-03-30 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
| CN106659730A (zh) | 2014-07-10 | 2017-05-10 | 里普利科股份有限公司 | 治疗b型肝炎和d型肝炎病毒感染的方法 |
| RU2017108238A (ru) | 2014-08-15 | 2018-09-17 | Эйдинкс, Инк. | Олигонуклеотиды-приманки для лечения боли |
| WO2016030863A1 (en) | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| MA42157A (fr) * | 2015-04-23 | 2018-02-28 | Geron Corp | Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent |
| PE20211783A1 (es) * | 2018-11-08 | 2021-09-08 | Aligos Therapeutics Inc | Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2021198958A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| WO2022109129A1 (en) * | 2020-11-20 | 2022-05-27 | Aligos Therapeutics, Inc. | Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| WO2022152869A1 (en) | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
| JP2024527380A (ja) | 2021-07-09 | 2024-07-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | 腎機能障害を有する個体へのオリゴヌクレオチドの使用 |
| EP4728073A1 (en) * | 2023-06-16 | 2026-04-22 | Ractigen Therapeutics | Oligonucleotide formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1019429A4 (en) * | 1997-08-20 | 2001-08-08 | Somagenics Inc | ANTISENSE THERAPEUTIC PRODUCTS WITH IMPROVED BINDING PROPERTIES AND METHODS OF USE |
| JP3667047B2 (ja) * | 1997-09-12 | 2005-07-06 | キヤノン株式会社 | 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法 |
| US6653467B1 (en) * | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| JP4836366B2 (ja) * | 2000-08-25 | 2011-12-14 | 雅文 松尾 | デュシェンヌ型筋ジストロフィー治療剤 |
| WO2005023829A1 (ja) | 2003-09-02 | 2005-03-17 | Japan Science And Technology Agency | 金属錯体型核酸 |
| WO2005026188A1 (ja) | 2003-09-08 | 2005-03-24 | Japan Science And Technology Agency | 金属錯体型核酸 |
| CA2613101A1 (en) * | 2005-07-01 | 2007-01-11 | Bioveris Corporation | Compositions and methods for detecting, amplifying, and/or isolating nucleic acids |
| WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
-
2011
- 2011-08-18 BR BR112013003875-6A patent/BR112013003875B1/pt not_active IP Right Cessation
- 2011-08-18 CN CN201410046103.1A patent/CN103768086B/zh active Active
- 2011-08-18 PT PT118176189T patent/PT2605794T/pt unknown
- 2011-08-18 SI SI201130985A patent/SI2605794T1/sl unknown
- 2011-08-18 HU HUE11817618A patent/HUE029521T2/en unknown
- 2011-08-18 MY MYPI2013000544A patent/MY160961A/en unknown
- 2011-08-18 CA CA2855690A patent/CA2855690C/en active Active
- 2011-08-18 NZ NZ606364A patent/NZ606364A/en not_active IP Right Cessation
- 2011-08-18 SG SG2013004957A patent/SG187165A1/en unknown
- 2011-08-18 LT LTEP11817618.9T patent/LT2605794T/lt unknown
- 2011-08-18 KR KR1020137007008A patent/KR101606495B1/ko not_active Expired - Fee Related
- 2011-08-18 EA EA201300259A patent/EA026660B1/ru unknown
- 2011-08-18 DK DK11817618.9T patent/DK2605794T3/en active
- 2011-08-18 JP JP2013524318A patent/JP5775581B2/ja active Active
- 2011-08-18 PH PH1/2013/500192A patent/PH12013500192B1/en unknown
- 2011-08-18 CN CN201180035946.6A patent/CN103052405B/zh active Active
- 2011-08-18 KR KR1020157017340A patent/KR20150082685A/ko not_active Withdrawn
- 2011-08-18 ES ES11817618.9T patent/ES2598556T3/es active Active
- 2011-08-18 KR KR20157007582A patent/KR20150039873A/ko not_active Withdrawn
- 2011-08-18 PL PL11817618T patent/PL2605794T3/pl unknown
- 2011-08-18 EP EP11817618.9A patent/EP2605794B1/en active Active
- 2011-08-18 AU AU2011291401A patent/AU2011291401B2/en not_active Ceased
- 2011-08-18 RS RS20160869A patent/RS55245B1/sr unknown
- 2011-08-18 WO PCT/CA2011/000956 patent/WO2012021985A1/en not_active Ceased
- 2011-08-18 CA CA2806616A patent/CA2806616C/en active Active
- 2011-08-18 MX MX2013001668A patent/MX340294B/es active IP Right Grant
- 2011-08-18 US US13/212,306 patent/US8513211B2/en active Active
- 2011-08-18 HR HRP20161333TT patent/HRP20161333T1/hr unknown
-
2013
- 2013-01-15 IL IL224237A patent/IL224237A/en active IP Right Grant
- 2013-01-18 ZA ZA2013/00497A patent/ZA201300497B/en unknown
- 2013-02-11 CO CO13027675A patent/CO6670525A2/es unknown
- 2013-02-13 CL CL2013000445A patent/CL2013000445A1/es unknown
- 2013-02-14 GT GT201300040A patent/GT201300040A/es unknown
- 2013-02-14 DO DO2013000041A patent/DOP2013000041A/es unknown
- 2013-02-19 CR CR20130069A patent/CR20130069A/es unknown
- 2013-02-19 EC ECSP13012449 patent/ECSP13012449A/es unknown
- 2013-02-20 CU CU2013000022A patent/CU20130022A7/es unknown
- 2013-05-30 US US13/905,318 patent/US8716259B2/en active Active
-
2016
- 2016-10-13 SM SM201600370T patent/SMT201600370B/it unknown
- 2016-10-17 CY CY20161101037T patent/CY1118207T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2013000041A (es) | Quelatos de oligonucleótidos para su uso en la supresión o reducción de reacciones en el punto de inyección | |
| CO2017005995A2 (es) | Composiciones para el cuidado bucal y métodos de uso | |
| AR091604A1 (es) | Potenciacion de autofagia o aumento de longevidad por administracion de urolitinas o precursores de las mismas, compuesto | |
| EP4335507A3 (en) | Combination therapy | |
| MX2015011955A (es) | Lipidos y composiciones de lipidos para el suministro de agentes activos. | |
| CR20140231A (es) | Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih | |
| MX2016001427A (es) | Inhibidores de syk. | |
| HK1212207A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| MX389250B (es) | Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos | |
| WO2015023976A3 (en) | Selective grp94 inhibitors and uses thereof | |
| UY32676A (es) | Nuevas quinazolinas sustituidas como fungicidas | |
| AR089269A1 (es) | Composiciones para el cuidado oral | |
| EP3412668A3 (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| BR112013010507A2 (pt) | compostos e composições para o tratamento de câncer | |
| NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
| BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
| EA201600398A1 (ru) | Тиенопиримидины в качестве ингибиторов mknk1 и mknk2 | |
| CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
| MX380847B (es) | Composiciones para el cuidado bucal y métodos de uso. | |
| MX382596B (es) | Composiciones que contienen arsénico y su uso en métodos de tratamiento. | |
| HK1220443A1 (zh) | 用作止痛药的全氢喹喔啉衍生物 | |
| EA201270728A1 (ru) | Пуриновые соединения | |
| MX361642B (es) | Composiciones antisépticas catiónicas. | |
| UA115583C2 (uk) | Азетидинілоксифенілпіролідинові сполуки |